Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

被引：12

作者：

Collier, Anderson B., III ^{[1
]}

Krailo, Mark D. ^{[2
]}

Dang, Ha M. ^{[2
]}

DuBois, Steven G. ^{[3
,4
]}

Hawkins, Douglas S. ^{[5
]}

Bernstein, Mark L. ^{[6
]}

Bomgaars, Lisa R. ^{[7
]}

Reed, Damon R. ^{[8
,9
,10
]}

Gorlick, Richard G. ^{[11
]}

Janeway, Katherine A. ^{[3
,4
]}

机构：

[1] Univ Mississippi, Dept Pediat, Med Ctr, 2500 North Sate St, Jackson, MS 38219 USA

[2] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA

[3] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA

[6] Dalhousie Univ, IWK Hlth Ctr, Port Williams, NS, Canada

[7] Baylor Coll Med, Dept Pediat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

[8] Johns Hopkins All Childrens Hosp, Canc Ctr, St Petersburg, FL USA

[9] Johns Hopkins All Childrens Hosp, Blood Disorders Inst, St Petersburg, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 12期

关键词：

event-free survival; Ewing sarcoma; objective response; outcome; phase; 2; trials; relapsed; REFRACTORY SOLID TUMORS; II TRIAL; CHEMOTHERAPY; CRITERIA;

D O I：

10.1002/pbc.29333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

引用

页数：5

共 20 条

[1] A Phase II Trial and Pharmacokinetic Study of Oxaliplatin in Children With Refractory Solid Tumors: A Children's Oncology Group Study
Beaty, Orren, III
Berg, Stacey
Blaney, Susan
Malogolowkin, Marcio
Krailo, Mark
Knight, Ronald
Schaiquevich, Paula
Stewart, Clinton
Chen, Zhengjia
Nelson, Marvin
Voss, Stephan
Ivy, S. Percy
Adamson, Peter C.
[J]. PEDIATRIC BLOOD & CANCER, 2010, 55 (03) : 440 - 445
[2] SARC-CTOS imaging symposium: Introduction to the problem from a clinical perspective
Benjamin, Robert S.
[J]. ONCOLOGIST, 2008, 13 : 1 - 3
[3] Ewing's sarcoma family of tumors: Current management
Bernstein, Mark
Kovar, Heinrich
Paulussen, Michael
Randall, R. Lor
Schuck, Andreas
Teot, Lisa A.
Juergens, Herbert
[J]. ONCOLOGIST, 2006, 11 (05) : 503 - 519
[4] ON THE VARIANCES OF ASYMPTOTICALLY NORMAL ESTIMATORS FROM COMPLEX SURVEYS
BINDER, DA
[J]. INTERNATIONAL STATISTICAL REVIEW, 1983, 51 (03) : 279 - 292
[5] Phase II trial of irinotecan in children with refractory solid tumors: A children's oncology group study
Bomgaars, Lisa R.
Bernstein, Mark
Krailo, Mark
Kadota, Richard
Das, Soma
Chen, Zhengjia
Adamson, Peter C.
Blaney, Susan M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4622 - 4627
[6] A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Bond, Mason
Bernstein, Mark L.
Pappo, Alberto
Schultz, Kirk R.
Krailo, Mark
Blaney, Susan M.
Adamson, Peter C.
[J]. PEDIATRIC BLOOD & CANCER, 2008, 50 (02) : 254 - 258
[7] Grier, 2019, 2019 CTOS ANN M 2019
[8] Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study
Hawkins, Douglas S.
Bradfield, Scott
Whitlock, James A.
Krailo, Mark
Franklin, Janet
Blaney, Susan M.
Adamson, Peter C.
Reaman, Gregory
[J]. PEDIATRIC BLOOD & CANCER, 2006, 47 (06) : 790 - 794
[9] Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Jacobs, Shana
Fox, Elizabeth
Krailo, Mark
Hartley, Gwen
Navid, Fariba
Wexler, Leonard
Blaney, Susan M.
Goodwin, Anne
Goodspeed, Wendy
Balis, Frank M.
Adamson, Peter C.
Widemann, Brigitte C.
[J]. CLINICAL CANCER RESEARCH, 2010, 16 (02) : 750 - 754
[10] Kalbfleisch J.D., 2002, The Statistical Analysis of Failure Time Data, V2nd, P439

← 1 2 →